{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:59:43Z","timestamp":1793501983599,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI140719"],"award-info":[{"award-number":["R01AI140719"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI140719"],"award-info":[{"award-number":["R01AI140719"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n            <jats:italic>Cryptococcus neoformans<\/jats:italic> is considered a critical fungal pathogen by the World Health Organization and developing a vaccine for cryptococcosis is a top priority. Here, we employed mRNAs encoding an antigen(s) packaged in lipid nanoparticles (LNPs) to develop vaccines for cryptococcosis. Remarkably, when coupled with capsule adjuvant, vaccination with <jats:italic>CDA1<\/jats:italic>-LNPs protected the vast majority of mice from the otherwise lethal cryptococcosis. These results support the promise of mRNA-LNP vaccines against fungal diseases.<\/jats:p>","DOI":"10.1038\/s41541-025-01079-z","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:43:37Z","timestamp":1738716217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Developing mRNA lipid nanoparticle vaccine effective for cryptococcosis in a murine model"],"prefix":"10.1038","volume":"10","author":[{"given":"Yeqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Meagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"1079_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40249-023-01073-4","volume":"12","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Cryptococcus neoformans, a global threat to human health. Infect. Dis. Poverty 12, 20 (2023).","journal-title":"Infect. Dis. Poverty"},{"key":"1079_CR2","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","volume":"22","author":"R Rajasingham","year":"2022","unstructured":"Rajasingham, R. et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect. Dis. 22, 1748\u20131755 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1079_CR3","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1128\/JCM.03177-13","volume":"52","author":"M Van Wyk","year":"2014","unstructured":"Van Wyk, M., Govender, N. P., Mitchell, T. G. & Litvintseva, A. P. Multilocus sequence typing of serially collected isolates of Cryptococcus from HIV-infected patients in South Africa. J. Clin. Microbiol. 52, 1921\u20131931 (2014).","journal-title":"J. Clin. Microbiol."},{"key":"1079_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3201\/eid1405.071312","volume":"14","author":"J Chen","year":"2008","unstructured":"Chen, J. et al. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg. Infect. Dis. 14, 755\u2013762 (2008).","journal-title":"Emerg. Infect. Dis."},{"key":"1079_CR5","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1128\/AAC.01800-12","volume":"57","author":"EW Bratton","year":"2013","unstructured":"Bratton, E. W. et al. Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. Antimicrob. Agents Chemother. 57, 2485\u20132495 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1079_CR6","unstructured":"WHO. WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action. https:\/\/www.who.int\/publications\/i\/item\/9789240060241 (2022)."},{"key":"1079_CR7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1080\/14760584.2023.2279570","volume":"22","author":"JL Chechi","year":"2023","unstructured":"Chechi, J. L. et al. Vaccine development for pathogenic fungi: current status and future directions. Exp. Rev. Vaccines 22, 1136\u20131153 (2023).","journal-title":"Exp. Rev. Vaccines"},{"key":"1079_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.vaccine.2019.10.051","volume":"38","author":"MM Hester","year":"2020","unstructured":"Hester, M. M. et al. Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. Vaccine 38, 620\u2013626 (2020).","journal-title":"Vaccine"},{"key":"1079_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target. Ther. 7, 94 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1079_CR10","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1079_CR11","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1079_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33157-4","volume":"13","author":"S Li","year":"2022","unstructured":"Li, S. et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat. Commun. 13, 5561 (2022).","journal-title":"Nat. Commun."},{"key":"1079_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrm.2017.103","volume":"19","author":"K Leppek","year":"2018","unstructured":"Leppek, K., Das, R. & Barna, M. Functional 5\u2019 UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat. Rev. Mol. Cell Biol. 19, 158\u2013174 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1079_CR14","doi-asserted-by":"publisher","first-page":"e0007566","DOI":"10.1371\/journal.pntd.0007566","volume":"13","author":"H Li","year":"2019","unstructured":"Li, H. et al. Unveil the transcriptional landscape at the Cryptococcus-host axis in mice and nonhuman primates. PLoS Negl. Trop. Dis. 13, e0007566 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1079_CR15","doi-asserted-by":"publisher","first-page":"e01433","DOI":"10.1128\/mBio.01433-15","volume":"6","author":"B Zhai","year":"2015","unstructured":"Zhai, B. et al. Development of protective inflammation and cell-mediated immunity against Cryptococcus neoformans after exposure to hyphal mutants. mBio 6, e01433\u201301415 (2015).","journal-title":"mBio"},{"key":"1079_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02785-21","volume":"13","author":"J Lin","year":"2022","unstructured":"Lin, J. et al. Immunoprotection against cryptococcosis offered by Znf2 depends on capsule and the hyphal morphology. mBio 13, e0278521(2022).","journal-title":"mBio"},{"key":"1079_CR17","doi-asserted-by":"publisher","first-page":"e0019823","DOI":"10.1128\/iai.00198-23","volume":"91","author":"T Pham","year":"2023","unstructured":"Pham, T., Li, Y., Watford, W. & Lin, X. Vaccination with a ZNF2(oe) strain of cryptococcus provides long-lastingprotection against cryptococcosis and is effective in immunocompromised hosts. Infect. Immun. 91, e0019823 (2023).","journal-title":"Infect. Immun."},{"key":"1079_CR18","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41590-023-01562-6","volume":"24","author":"M Ganley","year":"2023","unstructured":"Ganley, M. et al. mRNA vaccine against malaria tailored for liver-resident memory T cells. Nat. Immunol. 24, 1487\u20131498 (2023).","journal-title":"Nat. Immunol."},{"key":"1079_CR19","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1128\/iai.59.10.3700-3707.1991","volume":"59","author":"SJ Devi","year":"1991","unstructured":"Devi, S. J. et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59, 3700\u20133707 (1991).","journal-title":"Infect. Immun."},{"key":"1079_CR20","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/infdis\/165.6.1086","volume":"165","author":"A Casadevall","year":"1992","unstructured":"Casadevall, A. et al. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 165, 1086\u20131093 (1992).","journal-title":"J. Infect. Dis."},{"key":"1079_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41541-023-00786-9","volume":"8","author":"N Kunkeaw","year":"2023","unstructured":"Kunkeaw, N. et al. A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax. NPJ Vaccines 8, 187 (2023).","journal-title":"NPJ Vaccines"},{"key":"1079_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., Prabhu, S. A. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1079_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/cei.13356","volume":"198","author":"A Abraham","year":"2019","unstructured":"Abraham, A., Ostroff, G., Levitz, S. M. & Oyston, P. C. F. A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogens. Clin. Exp. Immunol. 198, 143\u2013152 (2019).","journal-title":"Clin. Exp. Immunol."},{"key":"1079_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.carbpol.2014.03.054","volume":"109","author":"H Yang","year":"2014","unstructured":"Yang, H., Han, S., Zhao, D. & Wang, G. Adjuvant effect of polysaccharide from fruits of Physalis alkekengi L. in DNA vaccine against systemic candidiasis. Carbohydr. Polym. 109, 77\u201384 (2014).","journal-title":"Carbohydr. Polym."},{"key":"1079_CR25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.molmed.2024.02.013","volume":"30","author":"C Bergstrom","year":"2024","unstructured":"Bergstrom, C., Fischer, N. O., Kubicek-Sutherland, J. Z. & Stromberg, Z. R. mRNA vaccine platforms to prevent bacterial infections. Trends Mol. Med. 30, 524\u2013526 (2024).","journal-title":"Trends Mol. Med."},{"key":"1079_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.tim.2021.09.007","volume":"30","author":"A Bruch","year":"2022","unstructured":"Bruch, A., Kelani, A. A. & Blango, M. G. RNA-based therapeutics to treat human fungal infections. Trends Microbiol. 30, 411\u2013420 (2022).","journal-title":"Trends Microbiol."},{"key":"1079_CR27","doi-asserted-by":"publisher","first-page":"e1007358","DOI":"10.1371\/journal.ppat.1007358","volume":"14","author":"CM Leopold Wager","year":"2018","unstructured":"Leopold Wager, C. M. et al. IFN-gamma immune priming of macrophages in vivo induces prolonged STAT1 binding and protection against Cryptococcus neoformans. PLoS Pathog 14, e1007358 (2018).","journal-title":"PLoS Pathog"},{"key":"1079_CR28","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3389\/fmicb.2015.00836","volume":"6","author":"A Rella","year":"2015","unstructured":"Rella, A. et al. Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development. Front Microbiol. 6, 836 (2015).","journal-title":"Front Microbiol."},{"key":"1079_CR29","doi-asserted-by":"publisher","first-page":"e0174624","DOI":"10.1128\/mbio.01746-24","volume":"15","author":"CA Specht","year":"2024","unstructured":"Specht, C. A. et al. Immunological correlates of protection mediated by a whole organism, Cryptococcus neoformans, vaccine deficient in chitosan. mbio 15, e0174624 (2024).","journal-title":"mbio"},{"key":"1079_CR30","doi-asserted-by":"publisher","first-page":"e1011115","DOI":"10.1371\/journal.ppat.1011115","volume":"19","author":"M Del Poeta","year":"2023","unstructured":"Del Poeta, M., Wormley, F. L. Jr. & Lin, X. Host populations, challenges, and commercialization of cryptococcal vaccines. PLoS Pathog 19, e1011115 (2023).","journal-title":"PLoS Pathog"},{"key":"1079_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1348-0421.2006.tb03773.x","volume":"50","author":"HA Yoon","year":"2006","unstructured":"Yoon, H. A. et al. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol. Immunol. 50, 83\u201392 (2006).","journal-title":"Microbiol. Immunol."},{"key":"1079_CR32","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","volume":"13","author":"JJ Suschak","year":"2017","unstructured":"Suschak, J. J., Williams, J. A. & Schmaljohn, C. S. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Hum. Vaccin. Immun.13, 2837\u20132848 (2017).","journal-title":"Hum. Vaccin. Immun."},{"key":"1079_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1128\/EC.00378-07","volume":"7","author":"S Frases","year":"2008","unstructured":"Frases, S., Nimrichter, L., Viana, N. B., Nakouzi, A. & Casadevall, A. Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell 7, 319\u2013327 (2008).","journal-title":"Eukaryot Cell"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01079-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01079-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01079-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:43:40Z","timestamp":1738716220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01079-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1079"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01079-z","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.M., Y.L., and X.L. (University of Georgia). Development of a mRNA Lipid Nanoparticle Vaccine Against Cryptococcosis. Disclosure Case No. 2023-111.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}